Tasimelteon Trial Results Have Been Released
A Vanda Pharmaceuticals study shows tasimelteon helped adults with delayed sleep-wake phase disorder fall asleep earlier.
Updated on Oct. 5, 2026 in Sleep Disorders
Live Poll
Do you trust that pharmaceutical companies are properly vetted when expanding drugs to new indications?
Vanda Pharmaceuticals has announced phase 3 clinical trial results demonstrating that tasimelteon effectively advances sleep onset in adults with delayed sleep-wake phase disorder. The company intends to use these findings to support a supplemental New Drug Application for its Hetlioz treatment.
Why it matters
Delayed sleep-wake phase disorder can significantly impact daily functioning, and this trial suggests a potential new therapeutic option for patients struggling to maintain a standard sleep schedule. The findings provide a data-driven path toward expanding the approved uses for an existing medication.
In this 28-day study of 40 adults, 60% of those receiving tasimelteon fell asleep at least 30 minutes earlier, compared to 15% of those in the placebo group. The treatment achieved a 37.1-minute difference in sleep onset advancement over the placebo arm.
The players
Vanda Pharmaceuticals
This is a biopharmaceutical company that develops and markets specialized therapies for sleep and psychiatric disorders.
The details
Participants in the trial were randomly assigned to receive a daily 20mg dose of tasimelteon or a placebo over a 28-day period. Researchers utilized sleep diaries to measure changes in sleep onset, confirming that the drug was effective in helping subjects fall asleep earlier than those who did not receive the active treatment.
Timeline
September 29, 2026: Vanda Pharmaceuticals released the study findings.
28 days: Duration of the clinical trial treatment period.
Health Landscape
This development represents a clinical expansion of the portfolio for Hetlioz, a medication already validated by the FDA approval of Hetlioz for non-24-hour sleep-wake disorder. The research aims to move the drug into a broader category of circadian rhythm conditions.
If the supplemental application is successful, this could offer a new prescription treatment option for individuals who struggle with the timing of their sleep-wake cycles. Patients should monitor future announcements regarding regulatory approval and consult healthcare providers about potential therapeutic availability.
The takeaway
These phase 3 results provide strong evidence for the potential efficacy of tasimelteon in addressing delayed sleep-wake phase disorder. Patients who experience chronic difficulties falling asleep at standard times may soon have an additional clinical pathway for management.
Further reading
Learn more about evolving treatment options for Sleep Disorders and how clinical research is advancing in this field.
More information
Read the full results in the Vanda Pharmaceuticals study news release.
Source note: This article includes information reported by Psychiatry Advisor.
Live Poll
Do you trust that pharmaceutical companies are properly vetted when expanding drugs to new indications?
